A practical reference on solvent: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-03-13 and is reviewed periodically as new material appears.
After a solvent is added, the vial is typically swirled or gently inverted rather than shaken vigorously. Shaking can introduce air and shear forces that promote foaming or aggregation, especially for longer peptides. Dissolution may take several minutes, and the solution should become clear unless the peptide is intentionally in suspension. Concentration is calculated from the mass of peptide stated on the vial label divided by the total liquid volume. If the dried peptide contains salts or counterions, the actual peptide content may be lower than the nominal mass.
Reconstitution is the process of adding a liquid to a lyophilized peptide so that the dried material dissolves into solution. Lyophilization removes water from a frozen peptide preparation under reduced pressure, leaving a porous solid or powder. The dried form often has greater long-term stability than a liquid because hydrolysis and oxidation are slowed. In laboratory work, reconstitution is usually the first step before dilution, analysis, or further experiments. The result is a stock solution whose concentration depends on the volume of solvent added and the amount of peptide in the vial.
Once reconstituted, a peptide solution is generally less stable than the dry powder. Hydrolysis, oxidation, aggregation, and microbial growth can change the preparation over time, so storage temperature and duration are practical concerns. Dividing a solution into single-use aliquots before freezing can reduce repeated freeze-thaw cycles, which may otherwise cause precipitation or loss of activity. The optimal storage conditions vary by peptide, and no single rule applies to all sequences. Records of solvent, concentration, date, and storage history help maintain traceability. Studies often report stability under defined conditions rather than universal shelf lives.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
| Property | Value | Notes |
|---|---|---|
| Physical state before solvent | Lyophilized powder or cake | Freeze-drying removes water under vacuum and leaves a porous solid. |
| Common reconstitution liquid | Sterile water or aqueous buffer | Compatibility depends on peptide sequence, charge, and pH requirements. |
| Typical solution pH | pH 3 to 7 | Acidic or slightly acidic conditions are common; some peptides need other ranges. |
| Appearance after dissolution | Clear to slightly opalescent solution | Cloudiness can indicate incomplete dissolution, aggregation, or undissolved excipients. |
| Concentration basis | Mass of peptide per volume of solvent | Label mass may include counterions or salts, so peptide content can differ. |
Storage stability of a reconstituted peptide depends on concentration, pH, buffer composition, and the presence of oxygen or microbial contaminants. Short-term storage is often at refrigerated temperatures, while longer-term storage may use freezing at -20 °C or -80 °C. Repeated warming and cooling can cause losses through adsorption or aggregation, so aliquots are preferred. Light-sensitive peptides require protection from ambient light. Sterile filtration may be used when microbial control is needed, but filters can adsorb peptides and reduce recovery.
Quality control after reconstitution usually includes visual inspection and instrumental analysis. A clear, particle-free solution is generally expected, but color and clarity can vary with sequence and buffer. Chromatographic separation can detect degradation products, while mass confirmation verifies molecular identity. pH measurement and osmolality checks may be relevant for certain applications. Documentation of lot number, solvent, and storage history supports reproducibility and helps distinguish preparation artifacts from sample degradation. Temperature logs and freeze-thaw counts add further context when results are reviewed.
After a peptide solution is prepared, its handling conditions influence how long it remains suitable for use. Solutions are typically separated into small portions to avoid repeated freeze-thaw cycles, which can promote aggregation or precipitation. Containers are chosen to minimize adsorption, especially for peptides that are hydrophobic or present at low concentration. Some laboratories use low-binding plastic tubes or add a carrier protein, although carrier addition can interfere with later analysis. Records usually note the solvent, date, and storage temperature for traceability.
After reconstitution, the peptide solution is less stable than the dried powder because water enables hydrolysis, oxidation, and microbial growth. Storage temperature, pH, buffer composition, and container material all affect how long the solution remains usable. Many peptides are kept at 2–8 °C for short-term work, while frozen aliquots at −20 °C or below are used for longer intervals. Repeated freeze-thaw cycles can cause aggregation or precipitation. The choice of storage condition should be based on stability data for the specific peptide.
Quality checks after reconstitution include visual inspection, pH measurement, and analytical methods such as reversed-phase high-performance liquid chromatography. These tests can detect insoluble material, degradation products, and changes in concentration. Mass spectrometry is often used to confirm molecular identity when the peptide sequence is known. Because a clear solution can still contain aggregates or modified peptide, visual clarity alone is not sufficient. Analytical results are compared with a reference standard or the pre-reconstitution certificate of analysis.
Once a peptide is in solution, its stability depends on temperature, pH, ionic strength, and the presence of oxygen or light. Many peptides are less stable in liquid form than as dry powders because hydrolysis, oxidation, and aggregation can proceed faster in water. Storage at low temperature slows these reactions but does not eliminate them. Some sequences are particularly sensitive to repeated freezing and thawing, which can cause precipitation or conformational changes. The container material and headspace also influence adsorption and surface-induced aggregation.
Practical handling often includes dividing a reconstituted solution into single-use aliquots to limit freeze-thaw cycling. Vials made of low-binding plastic or glass with inert closures are common, and some protocols add a carrier protein or bulking agent to reduce adsorption. Filtration through a sterile filter may be used when a sterile solution is required, but filters can retain peptide if binding occurs. Mixing is usually gentle; vigorous vortexing can introduce air-liquid interfaces that promote aggregation. Each of these steps involves trade-offs between sterility, recovery, and analytical accuracy.
Storage recommendations for reconstituted peptides vary by sequence and intended use, so general rules remain broad. A common laboratory practice is to keep solutions cold, sometimes frozen, and protected from light, but freezing itself can damage certain peptides. The pH of the solution may be adjusted to a range where the peptide is most stable, though changing pH can also alter solubility. Documentation of reconstitution date, solvent, concentration, and storage conditions supports reproducibility. Stability data for a specific peptide are generally established by direct measurement rather than assumed from related compounds.
== History == The new drug application for Vicoprofen was approved based on data from both single and multiple dose analgesia trials. The single dose analgesia studies occurred in multiple surgical settings, including dental, back, and abdominal/gynecologic surgery in the US and Puerto Rico. There were 1,537 patients enrolled over all trials, with 79% of the participants being female. There were 10 single dose analgesia trials included in the new drug application. All studies were similarly designed: after completion of a procedure in which pain was rated as moderate or severe, patients would be randomized into various treatment groups. The treatment groups included: ibuprofen only, hydrocodone only, Vicoprofen (hydrocodone/ibuprofen), and placebo. The participant's pain would then be tracked over the next several hours by the self reporting of pain scores. There were four multiple dose trials included in the new drug application. These studies were all completed in the US, in settings including burn unit, post-operatively, and chronic pain settings. A total of 683 patients were enrolled in all of the multiple dose trials, with 57% of the participants being women. These studies also looked at self reported pain intensities over a 5-day period of multiple dosing. In these studies, patients were either given the trial drug Vicoprofen or one of two an active controls: codeine with acetaminophen (Tylenol #3) or oxycodone with acetaminophen (Percocet), depending on the trial. Patients were allowed to take a dose as needed but no more than every 4 to 6 hours for up to 5 days.
People receiving eptifibatide are typically seriously ill and most of them are concomitantly treated with other drugs known to have the potential to cause significant side effects. Therefore, not all side effects listed as follows may be attributable to eptifibatide treatment alone: The major adverse event in the PURSUIT study was severe bleeding. Bleeding occurred as well at sites of clinical intervention (local sites) as at other sites (systemically) like urogenital bleeds. Sometimes, these events were severe enough to require transfusion of blood or plasma concentrates to stop bleeding and counteract anemia. Severe bleeds occurred in 4.4 and 4.7% of patients respectively depending on the infusion rate (0.5 μg/kg/min vs. 0.75 μg/kg/min). A few cases of death due to severe bleeding events attributable to drug therapy were reported. No cases of hemorrhagic stroke were seen. Thrombocytopenia of unknown origin (allergic reaction?) was also noticed in 0.2% of patients. Additionally, hypotension was seen frequently (6%). Cardiovascular failure was also frequent (2%) as were serious arrhythmias (ventricular fibrillation 1.5%, atrial fibrillation 6%). Severe allergic (anaphylactic) reactions occurred in almost 0.2% of patients. These reactions can be life-threatening and may be due to the peptide character of eptifibatide. Other side effects were rare and mild in nature and may not be connected to eptifibatide therapy.
=== Variations === Type 1 juncturae is mostly seen between the index and the middle fingers (second inter metacarpal space). Type 2 juncturae is observed mainly between the middle and the ring fingers (third inter-metacarpal space). Type 3 juncturae tendinum is mostly found between the ring and the little finger (fourth inter-metacarpal space). Normally, the extensor indicis proprius do not receive any juncture tendinum, but it is rarely seen and the mobility of the index finger is compromised. The absence of the tendon of the extensor digitorum communis to the little finger is associated with the thicker type 3r juncturae tendinum in the fourth intermetacarpal space. Hirai et al. reported type 1 junturae tendinum between the extensor digiti minimi and the extensor digitorum communis to the ring finger in 6% of the specimens.
The Lewis-acid-catalyzed cyanosilylation of aromatic aldehydes has also been carried out by Long and co-workers using a MOF of the formula Mn3[(Mn4Cl)3btt8(CH3OH)10]. This material contains a three-dimensional pore structure, with the pore diameter equaling 10 Å. In principle, either of the two types of Mn(II) sites could function as a catalyst. Noteworthy features of this catalyst are high conversion yields (for small substrates) and good substrate-size-selectivity, consistent with channellocalized catalysis.
== Structure and general properties == L- and D-amino acids are usually enantiomers. The exceptions are two amino acids with two stereogenic centers, threonine and isoleucine. Aside from those two special cases, L- and D-amino acids have identical properties (color, solubility, melting point) under many conditions. In the biological context however, which is chiral, these enantiomers can behave very differently. Thus, D-amino acids have low nutritional value, in part because they are not digested well. They contain a carboxyl group at one end and a side chain group at the other end. They also contain an amine and hydrogen group on opposite ends, depending on which enantiomer one is looking at. They also do attain a chiral carbon center. This is why the molecules can exist in different stereoisomeric forms, and the orientation of the radical groups is what is only different between these enantiomers. D-glyceraldehyde on the other hand, contains a carbonyl group and hydroxy (alcohol) groups with the chiral carbon in the center. The orientation is again, different for L-glyceraldehyde.
Sources: en.wikipedia.org
=== Black Consciousness and empowerment === Biko rejected the apartheid government's division of South Africa's population into "whites" and "non-whites", a distinction that was marked on signs and buildings throughout the country. Building on Fanon's work, Biko regarded "non-white" as a negative category, defining people in terms of an absence of whiteness. In response, Biko replaced "non-white" with the category "black", which he regarded as being neither derivative nor negative. He defined blackness as a "mental attitude" rather than a "matter of pigmentation", referring to "blacks" as "those who are by law or tradition politically, economically and socially discriminated against as a group in the South African society" and who identify "themselves as a unit in the struggle towards the realization of their aspirations". In this way, he and the Black Consciousness Movement used "black" in reference not only to Bantu-speaking Africans but also to Coloureds and Indians, who together made up almost 90% of South Africa's population in the 1970s. Biko was not a Marxist and believed that it was oppression based on race, rather than class, which would be the main political motivation for change in South Africa. He argued that those on the "white left" often promoted a class-based analysis as a "defence mechanism... primarily because they want to detach us from anything relating to race. In case it has a rebound effect on them because they are white".
Methenamine is provided in the form of 500 and 1,000 mg oral tablets. It is available both alone and in combination with the nonsteroidal anti-inflammatory drug (NSAID) sodium salicylate. Other combinations with other drugs, such as phenazopyridine, are also available. Methenamine is provided pharmaceutically alone as the hippuric acid (methenamine hippurate) and mandelic acid (methenamine mandelate) salts. The free base and other salts, including anhydromethylencitrate and sulfosalicylate, have also been marketed in some countries. Methenamine mandelate is provided as an enteric coated tablet and is taken four times daily, whereas methenamine hippurate is available only in non-coated tablet form and is taken twice daily. Non-coated methenamine tablets can have a chemical taste described as sweet, sour, and/or metallic. Methenamine is available both by prescription (by itself) and over the counter (in combinations). Over-the-counter formulations in combination with sodium salicylate (162.5 mg) contain a lower amount of methenamine of 162 mg methenamine free base per tablet compared to prescription formulations and are taken three times daily.
The riding drew headlines in the 2025 federal election, as it was initially called for the Bloc Québécois, but its recount led to Liberal candidate Tatiana Auguste winning by a margin of one vote, the narrowest result in the country. One voter in the district had her ballot returned as undeliverable due to an incorrect postal code printed on the pre-addressed ballot return envelope from Elections Canada; had her vote for the Bloc Québécois candidate been counted, the result would have been tied. After Elections Canada stated that it did not have legal standing to overturn the judicial recount, the Bloc Québécois announced it would be asking the Superior Court of Quebec for a new by-election to be held. On October 27, the court ruled that a byelection would not be held. On November 3, Sinclair-Desgagné announced that she would be appealing the ruling to the Supreme Court of Canada. On February 13, 2026, the Supreme Court annulled the result of the election in the riding, triggering a federal by-election. The by-election was held in April 2026, with Auguste winning by a margin of 731 votes, keeping the seat in Liberal control.
=== London Hospital === Florey was unhappy working at London Hospital; he disliked the long daily commute from Chobham that put his experimental work at the mercy of the railway timetable. In the summer Howard and Ethel lived in a flat in Belsize Park so he could devote more time to his work. He wrote up the results of the research he had done in New York on lacteals and lymphatic capillaries, which was published in the Journal of Physiology in 1927. Florey then embarked on writing a thesis for a fellowship at Gonville and Caius College, Cambridge, where he became an unofficial fellow in 1926. His thesis on "Physiology and pathology of the circulation of the blood and lymph" was accepted, and his fellowship awarded in 1927. He also continued his work on the secretion of mucus. London Hospital's facilities for the laboratory animals he needed for his research were unsatisfactory, so these experiments were carried out at Oxford and Cambridge. However, he was able to study the lacteals in patients undergoing abdominal surgery.
Sources: en.wikipedia.org
Reconstitution means adding a liquid to a dried peptide to form a solution. The dried material is usually a lyophilized powder or cake produced by freeze-drying. The resulting liquid is a stock solution that can be diluted or analyzed further.
Freeze-drying removes water and limits hydrolysis and oxidation during storage. The dried solid is generally more stable and easier to ship than a liquid. It also allows a defined amount of material to be sealed in a single vial.
No. Solubility depends on the amino acid sequence, charge, and hydrophobic content. Some peptides require buffer, dilute acid, dilute base, or a small amount of organic solvent. A supplier's recommended solvent is based on the specific peptide.
It means adding liquid to a lyophilized peptide powder so it dissolves into solution. The dry powder is not a finished liquid product, and the resulting concentration depends on the volume added. Complete dissolution should be visually confirmed before use.